ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2014³â 9¿ù 26ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F] |
GO1-GO4 (08:20~09:00) |
ÁÂÀå : ·ù±â¼º(°¡Å縯ÀÇ´ë) |
GO108:20~08:30 |
³²ÀºÁö ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Pancreatic adenocarcinoma up-regulated factor (PAUF) expression in ovarian mucinous adenocarcinoma associated with a poor prognosis |
GO208:30~08:40 |
¾ç¼±¿µ °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
ASC-US and LSIL triage in Korean women: Revisiting the 2012 ASCCP screening guidelines |
GO308:40~08:50 |
±èÁ¤Àº °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
Prediction model for 30-day morbidity after gynecological malignancy surgery |
GO408:50~09:00 |
ÇãÀºÁø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
The impact of the interval from surgery to initiation of chemotherapy (ISC) on survival in advanced epithelial ovarian cancer |
GO5-GO8 (09:00~09:40) |
ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë) |
GO509:00~09:10 |
¹èÈ¿¼÷ ±¹¸³¾Ï¼¾ÅÍ |
Predictive factor and risk group analysis for the local recurrence/persistent disease in
cervical cancer patients who underwent primary concurrent chemoradiotherapy (CCRT) |
GO609:10~09:20 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Laparoscopic surgical management of localized recurrent ovarin cancer |
GO709:20~09:30 |
ÀÓ¸íö ±¹¸³¾Ï¼¾ÅÍ |
A simple new technique of diaphragmatic peritonectomy: hand-pushing down with anchoring both ends |
GO809:30~09:40 |
ÀÌÁ¤¿ø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Anti-angiogenic Effect of Itraconazole in Epithelial Ovarian Cancer |
GO9-GO12 (09:40~10:20) |
ÁÂÀå : ³²°èÇö(¼øõÇâÀÇ´ë) |
GO909:40~09:50 |
¼µ¿ÈÆ ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Survival impact of surgical spillage in stage I clear cell carcinoma of ovary: Korean multicenter study. |
GO1009:50~10:00 |
Á¤Çʽ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Poor prognosis after conservative surgery in stage I mucinous epithelial ovarian cancer |
GO1110:00~10:10 |
ÀÌÁ¤À± ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
A low-risk group for parametrial involvement is accurately identified by criteria used in ongoing studies and new criteria using MRI in microscopic stage IB1 cervical cancer |
GO1210:10~10:20 |
ÀÓ¸íö ±¹¸³¾Ï¼¾ÅÍ |
Colon cancer as a second primary cancer after endometrial cancer based on shared etiology: a proof of concept study |
GO13-GO16 (11:00~11:40) |
ÁÂÀå : ¹®Çý¼º(ÀÌÈÀÇ´ë) |
GO1311:00~11:10 |
±â°æµµ °µ¿°æÈñ´ëÇб³º´¿ø »êºÎÀΰú |
XAF1 is activated by TNF¥á and mediated TNF¥á-induced apoptosis in ovarian cancer cells |
GO1411:10~11:20 |
ÀÓ°¡¿ø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Long non-coding RNA HOXA11as is associated with survival in advanced epithelial ovarian cancer |
GO1511:20~11:30 |
±¸À¯Áø °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
Discordance of histopathologic diagnosis between colposcopy-guided biopsy and conization in high-grade cervical intraepithelial lesions |
GO1611:30~11:40 |
Á¤Çʽ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Diagnostic value of combined 18F-FDG positron emission tomography/computed tomography in recurrent epithelial ovarian cancer with non-disseminated lesions |
GO17-GO20 (11:40~12:20) |
ÁÂÀå : À̼±°æ(°æÈñÀÇ´ë) |
GO1711:40~11:50 |
ÀÌÁöÀ± ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Makorin Ring Finger Protein 1 (MKRN1) as an adjunct marker in liquid-based cervical cytology |
GO1811:50~12:00 |
ÀÌÁö¼± ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Predicting model for lymph node metastasis using preoperative tumor grade, transvaginal
ultrasound, and serum CA-125 level in patients with endometrial cancer |
GO1912:00~12:10 |
·ù±âÁø °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Clinical Significance of HPV DNA Co-testing in Korean Women with atypical squamous
cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H). |
GO2012:10~12:20 |
ÀÌÁö¿µ Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Cytokeratin 19 and human papilloma virus in lymph node of cervical cancer patients with intermediate risk factors |
GO21-GO24 (12:20~13:00) |
ÁÂÀå : À̱âÇå(°üµ¿ÀÇ´ë) |
GO2112:20~12:30 |
½Å¼ÒÁø °è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú |
The Hsp90 Inhibitor SY-016, Induces G2/M Arrest and Apoptosis in Paclitaxel-resistant Human Ovarian Cancer Cells |
GO2212:30~12:40 |
ÀÌ¹Î¾Æ ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
Synergistic effect of HPV E6/E7 siRNA in combination with Cisplatin on Basal dynamic
studies of TP53 |
GO2312:40~12:50 |
¼Õ±Ý¼± ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Chemosensitivity testing based on gene expression profiling in patients with ovarian cancer |
GO2412:50~13:00 |
±èÇüÁÖ ¿¬¼¼ÀÇ´ë °³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Forkhead box P1 (Foxp1) in cervical cancer |
GO25-GO28 (14:00~14:40) |
ÁÂÀå : °í¼®ºÀ(´ë±¸°¡Å縯ÀÇ´ë) |
GO2514:00~14:10 |
±èÁ¤Áø ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Comparison of barbed suture versus traditional suture in laparoendoscopic single-site myomectomy |
GO2614:10~14:20 |
¼ÕÁÖÇõ ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Cutoff value of pre- and post-cone HR-HPV load predicting residual/recurrent disease
after conization in high-grade intraepithelial neoplasia and microinvasive carcinoma of the
uterine cervix |
GO2714:20~14:30 |
À̽ÂÁ¤ °æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Single-port nerve sparing laparoscopic radical hysterectomy with extended node dissection for cervical cancer |
GO2814:30~14:40 |
¹èÀ縸 ÇѾç´ëÇб³º´¿ø »êºÎÀΰú |
Laparoscopic Cytoreductive Surgery in Women with Epithelial Ovarian Cancer |
GO29-GO33 (14:40~15:30) |
ÁÂÀå : ÇѼ¼ÁØ(Á¶¼±ÀÇ´ë) |
GO2914:40~14:50 |
±èÁöÈñ ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Detecting asymptomatic recurrence in early stage endometrial cancer- the value of vaginal cytology, imaging studies and CA-125 |
GO3014:50~15:00 |
±è¿¬¼± °í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú |
Clinical impact of the number of the retrieved pelvic lymph nodes in epithelial ovarian cancer |
GO3115:00~15:10 |
±èÈñÁ¤ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Steroid Receptor Activator induces tumor proliferation and invasion through the Notch pathway in the human ovarian cancer |
GO3215:10~15:20 |
¼µ¿¼ö ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers
|
GO3315:20~15:30 |
ÀÌ´Ù¿ë ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Prognosis and Associated Factors in Neuroendocrine Cervical Carcinoma (NECC) |